Literature DB >> 29353720

((S)-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo-β-lactamase inhibitors: Synthesis, kinetic and crystallographic studies.

Sha Liu1, Li Jing1, Zhu-Jun Yu1, Chengyong Wu2, Yongxiang Zheng1, En Zhang3, Qiang Chen2, Yamei Yu2, Li Guo1, Yong Wu4, Guo-Bo Li5.   

Abstract

The emergence and global spread of metallo-β-lactamase (MBL) mediated resistance to almost all β-lactam antibacterials poses a serious threat to public health. Since no clinically useful MBL inhibitors have been reported, there is an urgent need to develop new potent broad-spectrum MBL inhibitors effective against antibacterial resistance. Herein, we synthesized a set of 2-substituted ((S)-3-mercapto-2-methylpropanamido) acetic acid derivatives, some of which displayed potent inhibition with high ligand efficiency to the clinically relevant MBL subtypes, Verona Integron-encoded MBL (VIM)-2 and New Delhi MBL (NDM)-1. Kinetic studies revealed that the inhibitors are not strong zinc chelators in solution, and they bind reversibly to VIM-2 but dissociate very slowly. Crystallographic analyses revealed that they inhibit VIM-2 via chelating the active site zinc ions and interacting with catalytically important residues. Further cell- and zebrafish-based assays revealed that the inhibitors slightly increase susceptibility of E. coli cells expressing VIM-2 to meropenem, and they have no apparent toxicity to the viability of HEK293T cells and the zebrafish embryogenesis.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antibacterial resistance; Crystallography; Inhibitor design; Metallo-β-lactamase (MBL); VIM-2

Mesh:

Substances:

Year:  2018        PMID: 29353720     DOI: 10.1016/j.ejmech.2018.01.032

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

Review 1.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 2.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

3.  NMR Characterization of the Influence of Zinc(II) Ions on the Structural and Dynamic Behavior of the New Delhi Metallo-β-Lactamase-1 and on the Binding with Flavonols as Inhibitors.

Authors:  Gwladys Rivière; Saoussen Oueslati; Maud Gayral; Jean-Bernard Créchet; Naïma Nhiri; Eric Jacquet; Jean-Christophe Cintrat; François Giraud; Carine van Heijenoort; Ewen Lescop; Stéphanie Pethe; Bogdan I Iorga; Thierry Naas; Eric Guittet; Nelly Morellet
Journal:  ACS Omega       Date:  2020-04-28

4.  Discovery of [1,2,4]Triazole Derivatives as New Metallo-β-Lactamase Inhibitors.

Authors:  Chen Yuan; Jie Yan; Chen Song; Fan Yang; Chao Li; Cheng Wang; Huiling Su; Wei Chen; Lijiao Wang; Zhouyu Wang; Shan Qian; Lingling Yang
Journal:  Molecules       Date:  2019-12-23       Impact factor: 4.411

5.  N-Aryl mercaptoacetamides as potential multi-target inhibitors of metallo-β-lactamases (MBLs) and the virulence factor LasB from Pseudomonas aeruginosa.

Authors:  Samir Yahiaoui; Katrin Voos; Jörg Haupenthal; Thomas A Wichelhaus; Denia Frank; Lilia Weizel; Marco Rotter; Steffen Brunst; Jan S Kramer; Ewgenij Proschak; Christian Ducho; Anna K H Hirsch
Journal:  RSC Med Chem       Date:  2021-07-29

6.  Drug Repurposing of the Unithiol: Inhibition of Metallo-β-Lactamases for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections.

Authors:  Vitaly G Grigorenko; Maria G Khrenova; Irina P Andreeva; Maya Yu Rubtsova; Anastasia I Lev; Tatiana S Novikova; Elena V Detusheva; Nadezhda K Fursova; Ivan A Dyatlov; Alexey M Egorov
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

7.  Discovery of mercaptopropanamide-substituted aryl tetrazoles as new broad-spectrum metallo-β-lactamase inhibitors.

Authors:  Yu-Hang Yan; Jian Chen; Zhen Zhan; Zhu-Jun Yu; Gen Li; Li Guo; Guo-Bo Li; Yong Wu; Yongxiang Zheng
Journal:  RSC Adv       Date:  2020-08-25       Impact factor: 3.361

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.